WS
NBRV

Wedbush Securities’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Wedbush Securities’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-524
Closed -$2K – 1128
2022
Q2 		$2K Hold
524
– – ﹤0.01% 1069
2022
Q1 		$6K Hold
524
– – ﹤0.01% 1096
2021
Q4 		$8K Sell
524
-80
-13% -$1.89K ﹤0.01% 1169
2021
Q3 		$18K Buy
604
+204
+51% +$5.76K ﹤0.01% 1161
2021
Q2 		$14K Buy
+400
New +$14.9K ﹤0.01% 1154
2020
Q4 		– Sell
-84
Closed -$11K – 1041
2020
Q3 		$11K Hold
84
– – ﹤0.01% 927
2020
Q2 		$14K Hold
84
– – ﹤0.01% 950
2020
Q1 		$12K Buy
84
+8
+11% +$2.45K ﹤0.01% 869
2019
Q4 		$25K Sell
76
-29
-28% -$13.3K ﹤0.01% 980
2019
Q3 		$52K Sell
105
-186
-64% -$105K 0.01% 938
2019
Q2 		$177K Sell
291
-84
-22% -$51.5K 0.02% 850
2019
Q1 		$229K Sell
375
-39
-9% -$21.3K 0.02% 714
2018
Q4 		$151K Buy
414
+46
+13% +$24.7K 0.02% 723
2018
Q3 		$249K Sell
368
-58
-14% -$41.1K 0.03% 675
2018
Q2 		$371K Buy
+426
New +$488K 0.05% 477

Other funds holding NBRV

VFA
Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities's NBRV Position: Q3 2022 in Review

Wedbush Securities sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 524 shares — an estimated $2K sold.

Wedbush Securities first reported a position in NBRV in Q2 2018 and held it in 15 quarters. The position peaked at $371K in Q2 2018. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

  • Wedbush Securities reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
  • Wedbush Securities sold 524 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2022, an estimated $2K.
  • Wedbush Securities first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2018 and held it in 15 quarters.
  • Wedbush Securities's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $371K in Q2 2018.
  • 13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on Wedbush Securities's 13F filing for Q3 2022, filed 18 Oct 2022.